Grit­stone bio’s stock dips af­ter it shares more da­ta from failed Phase 2 col­orec­tal can­cer tri­al

Months af­ter an­nounc­ing the fail­ure of a mid-stage tri­al for its per­son­al­ized neoanti­gen vac­cine in can­cer, Grit­stone bio re­port­ed more da­ta that it plans to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER